These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12769689)

  • 61. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
    Indraccolo S
    Adv Exp Med Biol; 2013; 734():37-52. PubMed ID: 23143974
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Can contrast-enhanced US with targeted microbubbles monitor the response to antiangiogenic therapies?
    Kruskal JB
    Radiology; 2008 Feb; 246(2):339-40. PubMed ID: 18227533
    [No Abstract]   [Full Text] [Related]  

  • 63. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
    Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Heterogeneity of tumor endothelial cells and drug delivery.
    Hida K; Maishi N; Sakurai Y; Hida Y; Harashima H
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):140-147. PubMed ID: 26626622
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin.
    Shimizu K; Asai T; Fuse C; Sadzuka Y; Sonobe T; Ogino K; Taki T; Tanaka T; Oku N
    Int J Pharm; 2005 May; 296(1-2):133-41. PubMed ID: 15885465
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The role of angiogenesis in solid tumours: an overview.
    Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K
    Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.
    Sepp-Lorenzino L; Thomas KA
    Expert Opin Investig Drugs; 2002 Oct; 11(10):1447-65. PubMed ID: 12387705
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tumour-Endothelial Cell Communications: Important and Indispensable Mediators of Tumour Angiogenesis.
    Lopes-Bastos BM; Jiang WG; Cai J
    Anticancer Res; 2016 Mar; 36(3):1119-26. PubMed ID: 26977007
    [TBL] [Abstract][Full Text] [Related]  

  • 69. COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models.
    Kim HS; Sharma A; Ren WX; Han J; Kim JS
    Biomaterials; 2018 Dec; 185():63-72. PubMed ID: 30223141
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Angiogenesis in cancer.
    Nishida N; Yano H; Nishida T; Kamura T; Kojiro M
    Vasc Health Risk Manag; 2006; 2(3):213-9. PubMed ID: 17326328
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
    Ribatti D
    Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies.
    Maes H; Olmeda D; Soengas MS; Agostinis P
    FEBS J; 2016 Jan; 283(1):25-38. PubMed ID: 26443003
    [TBL] [Abstract][Full Text] [Related]  

  • 75. III. Angiogenesis: complexity of tumor vasculature and microenvironment.
    Furuya M; Yonemitsu Y; Aoki I
    Curr Pharm Des; 2009; 15(16):1854-67. PubMed ID: 19519428
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cancer Phytotherapy: Recent Views on the Role of Antioxidant and Angiogenesis Activities.
    Bahmani M; Shirzad H; Shahinfard N; Sheivandi L; Rafieian-Kopaei M
    J Evid Based Complementary Altern Med; 2017 Apr; 22(2):299-309. PubMed ID: 26753686
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cucurbitacin B inhibits tumor angiogenesis by triggering the mitochondrial signaling pathway in endothelial cells.
    Piao XM; Gao F; Zhu JX; Wang LJ; Zhao X; Li X; Sheng MM; Zhang Y
    Int J Mol Med; 2018 Aug; 42(2):1018-1025. PubMed ID: 29717773
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
    Abu Lila AS; Ishida T; Kiwada H
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y; Liu Q
    Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.
    Ansari MJ; Bokov D; Markov A; Jalil AT; Shalaby MN; Suksatan W; Chupradit S; Al-Ghamdi HS; Shomali N; Zamani A; Mohammadi A; Dadashpour M
    Cell Commun Signal; 2022 Apr; 20(1):49. PubMed ID: 35392964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.